TITLE 310. OKLAHOMA STATE DEPARTMENT OF HEALTH
CHAPTER 550. NEWBORN SCREENING PROGRAM

RULEMAKING ACTION:
PERMANENT final adoption

RULES:
310:550-1-1. [AMENDED]
310:550-1-2. [AMENDED]
Subchapter 3. Testing of Newborns
310:550-3-1. [AMENDED]
Subchapter 5. Blood Specimen Collection
310:550-5-1. [AMENDED]
310:550-5-2. [AMENDED]
Subchapter 7. Hospital Recording Records
310:550-7-1. [AMENDED]
Subchapter 11. Advisory Committee
310:550-11-1. [AMENDED]
Subchapter 13. Parent and Health Care Provider Education
310:550-13-1. [AMENDED]
Subchapter 17. Follow-up for Physicians
310:550-17-1. [AMENDED]
Subchapter 19. Reporting
310:550-19-1. [AMENDED]
Subchapter 21. Information
310:550-21-1. [AMENDED]
Subchapter 23. Standards, Procedures, and Follow-Up for Certified Laboratories
310:550-23-1. [AMENDED]

AUTHORITY:
Commissioner of the Oklahoma State Department of Health; 63 O.S. § 1-104

SUBMISSION OF PROPOSED RULES TO GOVERNOR AND CABINET SECRETARY:
October 20, 2020

COMMENT PERIOD:
November 16, 2020 through December 16, 2020

PUBLIC HEARING:
December 18, 2020

ADOPTION:
January 25, 2021

SUBMISSION OF ADOPTED RULES TO GOVERNOR AND LEGISLATURE:
January 25, 2021

LEGISLATIVE APPROVAL:
Approved June 11, 2021 by HJR 1046

FINAL ADOPTION:
June 11, 2021

EFFECTIVE:
September 11, 2021

SUPERSEDED EMERGENCY ACTIONS:
n/a

INCORPORATIONS BY REFERENCE:
n/a

GIST/ANALYSIS:
The rule amendments replaced the terms "Mental Retardation" and "Mental and Physical Retardation" with "Developmental Disabilities" as it is outdated and may be considered insensitive and disrespectful. Pursuant to 25 O.S. § 40, statutes and administrative rules should avoid language that equates persons with their condition and should replace non-respectful language by referring to persons with disabilities as persons first. In order to promote consistency, it is necessary to amend all chapters that contain this terminology, even if those chapters do not equate persons with their condition. There are multiple instances of simplifying and clarifying language, correcting minor grammatical errors, and ensuring terms are used consistently throughout the document. Duplicative language was removed in multiple instances. Language regarding sections of the Newborn Screening Refusal Form and Pulse Oximetry Screening Result Form was simplified by removing the names of individual fields that need to be completed to now state "must be completed in its entirety". This was done in an effort to align with the Governor's Executive order.

CONTACT PERSON:
Audrey C. Talley, Agency Rule Liaison, Oklahoma State Department of Health, 123 Robert S. Kerr Avenue, Oklahoma City, OK 73102, 405-426-8563. AudreyT@health.ok.gov.

PURSUANT TO THE ACTIONS DESCRIBED HEREIN, THE FOLLOWING RULES ARE CONSIDERED FINALLY ADOPTED AS SET FORTH IN 75 O.S., SECTIONS 250.3 (5) AND 308 (E), WITH AN EFFECTIVE DATE OF SEPTEMBER 11, 2021

SUBCHAPTER 1. GENERAL PROVISIONS

310:550-1-1. Purpose
Under 63 O.S., Sections 1-533 and 1-534 the following rules and regulations are established concerning the screening of all infants born in Oklahoma for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), infants shall be screened for biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, and establishment of short-term follow-up services, and approval by the Commissioner of Health. This chapter also establishes the following rules and regulations concerning pulse oximetry screening of all infants born at a birthing facility in Oklahoma for critical congenital heart disease (CCDH) via pulse oximetry screening to be performed by the birthing facility pursuant to 63 O.S. Section 1-550.5.

310:550-1-2. Definitions
The following words or terms, when used in this Chapter, shall have the following meaning, unless the context clearly indicates otherwise:

"Amino Acid Disorders" refers to a group of inherited metabolic conditions in which the body is unable to metabolize or process amino acids properly due to a defective enzyme function. This causes an amino acid or protein build up in the body. If not treated early in life, these defects can cause developmental disability or death. Each amino acid disorder is associated with a specific enzyme deficiency. Treatment depends on the specific amino acid disorder.

"Biotinidase Deficiency" means an inherited disease caused by the lack of an enzyme that recycles the B vitamin biotin, which if not treated, may cause serious complications, including coma and death.

"Birth Defects Registry" means a registry established by the Commissioner of Health to monitor and track birth defects for all infants born in Oklahoma.

"Birthing Facility" means a facility that provides care during labor and delivery, and to the newborn infants. This includes a unit of a hospital that is licensed and accredited to provide birthing services, or a
freestanding birthing center.

"Certified Laboratory" refers to the Oklahoma State Public Health Laboratory and/or a laboratory approved by the Oklahoma State Department of Health to conduct newborn screening.

"CCHD Screening" means the screening test for the detection of critical congenital heart disease that is recommended by the United States Department of Health and Human Services.

"CLIA '88" means the Clinical Laboratory Improvement Amendments of 1988, public law 100-578. This amendment applies to the Federal Law that governs laboratories who examine human specimens for the diagnosis, prevention, or treatment of any disease or impairment, or the assessment of the health of human beings.

"Confirmatory Testing" means definitive laboratory testing needed to confirm a diagnosis.

"Congenital Adrenal Hyperplasia" or "CAH" means the most common form of CAH, 21-hydroxylase deficiency. This genetic disorder is caused by the lack of an enzyme that the adrenal gland uses to process hormones. Serious loss of body salt and water can result in death. In girls the genitalia may appear as those of a male's, and can result in incorrect sex assignment. Hormone treatment is required for life.

"Congenital Hypothyroidism" means a disease caused by a deficiency of thyroid hormone (thyroxine) production, which if not treated, leads to developmental and physical disability. This is usually treated with thyroid hormone to prevent mental and physical disability.

"Critical Congenital Heart Disease" means a congenital heart defect that places an infant at significant risk for disability or death if not diagnosed soon after birth.

"Cystic Fibrosis" means a multisystem genetic disorder in which defective chloride transport across mucous membranes causes dehydration of secretions. The result is a production of a thick, viscous mucus that clogs the lungs, disrupts the normal function of the lungs, gut, and pancreas. This leads to chronic lung infections, fatal lung disease, and also interferes with problems with digestion. Early detection and treatment can prevent malnutrition, and enhance surveillance and treatment of lung infections.

"Days of Age" means the age of a newborn in 24-hour periods so that a newborn is one day of age 24 hours following the hour of birth for both blood spot screening and pulse oximetry screening.

"Department" refers to the Oklahoma State Department of Health.

"Discharge" means release of the newborn from care and custody of a perinatal licensed health facility to the parents or into the community.

"Disorder" means any condition detectable by newborn screening that allows opportunities, not available without screening, for early treatment and management to prevent developmental disability and/or reduce infant morbidity and mortality.

"Echocardiogram" means a test that uses ultrasound to provide an image of the heart.

"Fatty Acid Oxidation Disorders" refers to a group of inherited metabolic conditions in which the body is unable to oxidize (breakdown) fatty acids for energy due to a defective enzyme function. If not treated early in life, this defect may cause developmental disability or death.

"Galactosemia" means an inherited disease caused by the body's failure to break down galactose due to a defective enzyme function, which if not treated early in life, may cause developmental disability or death.

"Hemoglobin" means a protein in the red blood cell that carries oxygen.

"Hemoglobinopathy" means an inherited hemoglobin disorder associated with structural abnormality of hemoglobin, anemia, and variable impaired ability of the red blood cells to carry oxygen.

"Infant" means a child 6 months of age and under younger.

"Infant's Physician" means the licensed medical or osteopathic physician listed by the submitter or the individual responsible for the medical care of the newborn infant after discharge from the birthing facility.

"Initial Specimen" means the first blood specimen collected subsequent to birth, pursuant to these procedures.

"Long-term Follow-up" means follow-up services that begin with diagnosis and treatment and continues throughout the lifespan. This includes parent education, networking, referral, and care coordination.
"Medical Home" means a Planned Health Care Provider.

"Medium-chain acyl coenzyme A dehydrogenase deficiency" or "MCAD" means a genetic disorder of fatty acid metabolism. This disorder can cause metabolic crisis when an infant/child fasts. This crisis can lead to seizures, failure to breathe, cardiac arrest, and death. Treatment is effective by preventing fasting.

"Mucopolysaccharidosis Type I" or "MPS I" means a condition in which individuals are missing an enzyme to break down large sugar molecules. This disorder can impact many different organs and tissue leading to developmental delays if not identified and treated early.

"Newborn" means an infant thirty (30) days of age and younger.

"Newborn Screening" or "newborn screening tests" means the use of various laboratory and clinical tests to screen infants for certain inherited disorders where a potential net benefit and availability of effective treatments have been demonstrated of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health. Also includes critical congenital heart disease (CCHD) via pulse oximetry screening conducted by birthing facilities on all newborns born in the state of Oklahoma.

"Newborn Screening Form Kit" or "Form Kit" means an a filter paper approved by the Department for collection of the newborn screening specimen and associated demographic data.

"Newborn Screening Laboratory" means a laboratory operated by the Department or a laboratory certified by the Department to conduct the tests and carry out the follow-up required by these procedures.

"Newborn Screening Program" or "The Program" refers to the Public Health Laboratory and Short-term Follow-up Program at the Department.

"Newborn Screening Program Coordinator" refers to the coordinator of the Short-term Follow-up Program at the Department.

"Organic Acid Disorders" refers to a group of inherited metabolic conditions in which the body is unable to metabolize or process organic acids properly due to a specific enzyme deficiency, which if not treated early in life can cause the accumulation of organic acids in blood and urine. The accumulated compounds or their metabolites are toxic, resulting in the clinical features of these disorders including developmental disability and death.

"Pediatric Sub-Specialist Subspecialist" means a physician licensed in Oklahoma, board certified in pediatrics and board certified in a pediatric sub-specialty subspecialty, of pediatric endocrinology, pediatric pulmonology, or pediatric hematology, or a physician licensed in Oklahoma, board certified in pediatrics whose primary area of practice is pediatric endocrinology, pediatric hematology, pediatric pulmonology, or metabolic specialist.

"Phenylketonuria" or "PKU" means an inherited disease caused by the body's failure to convert the amino acid phenylalanine to tyrosine due to defective enzyme function, which if not treated early in life causes developmental disability.

"Planned Health Care Provider" or "Medical Home" means the health care provider who will be providing health care for the infant after discharge from the hospital.

"Pompe" or "Pompe Disease" means a condition in which individuals are missing an enzyme to break down complex sugar molecules. This disorder can lead to muscle weakness, poor muscle tone and heart defects if not identified and treated early.

"Premature Infant Newborn" means an infant newborn weighing less than 2500 grams or any live birth before the thirty-seventh week of gestation.

"Pulse Oximetry Screening" means a test using a device placed on an extremity to measure the percentage of oxygen in the blood.

"Repeat Specimen" means an additional newborn screening specimen to be collected after the initial
"Satisfactory Specimen" means a blood specimen collected using a single form Kit which that is suitable in both blood quantity and quality to perform newborn screening for phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell disease, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, Severe Combined Immunodeficiency (SCID) spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health the disorders approved by the Commissioner of Health and listed in 310:550-1-1. All requested demographic information on the form Kit must be completed. Federal CLIA '88 regulations require that the form Kit's laboratory requisition does not include the

"Screened" means a specimen that has been collected and tested on an infant less than 6 months of age.

"Screening" means a test to sort out well persons who may have a disease or defect from those who may not. A screening test is not intended to be diagnostic.

"Severe Combined Immunodeficiency" means a group of potentially fatal inherited disorders related to the immune system, which if not treated, can lead to potentially deadly infections.

"Short-term Follow-up" includes services provided by the Department and the health care provider that begins when the laboratory reports an abnormal or unsatisfactory screen result, or a result is not reported due to specific collection criteria, and ends with a diagnosis of normal "normal", the infant is lost to follow-up (repeat testing not achieved), the parent(s) or guardian(s) refuse follow-up, or the affected infant receives with appropriate treatment and referral has been initiated to a pediatric subspecialist.

"Sick Infant Newborn" means an infant newborn with any condition or episode marked by pronounced deviation from the normal healthy state; illness.

"Sickle Cell Disease" means an inherited disease caused by abnormal hemoglobin(s)(hemoglobinopathy), which may cause anemia and variable impaired ability of the red blood cells to carry oxygen, and if not treated early in life, may result in severe illness, developmental disability or death (one variation is commonly referred to as sickle cell anemia).

"Specimen" means blood collected on the filter paper Newborn Screening Form Kit.

"Spinal Muscular Atrophy" or "SMA" means conditions in which the loss of specialized nerves cells, which control muscle movement leads to progressive weakness and atrophy of muscles used for crawling, walking, sitting up and controlling head movement, and developmental disability. In severe cases, the muscles used for breathing and swallowing may be affected.

"Submitter" means a hospital, other facility, or physician submitting a blood specimen on a Newborn Screening specimen Form Kit.

"The Program" means the Newborn Screening Program in the Department.

"Transfer" means release of the newborn or infant from care and custody from one licensed health facility to another.

"Unsatisfactory Specimen" means a blood specimen which submitted on a Form Kit that is not collected on a form Kit and/or is not suitable in blood quantity and quality to perform screening for phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell disease, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health the disorders approved by the Commissioner of Health and listed in 310:550-1-1 and/or Federal CLIA '88 regulations are not followed and the form Kit's laboratory requisition does not include the
"X-Linked Adrenoleukodystrophy" or "X-ALD" means a condition in which affecting the nervous system and adrenal glands are affected. Impact to the nervous system reduces in which the ability of the nerves to relay information to the brain and the adrenal glands to make certain hormones (adrenocortical insufficiency) are impacted. Impact to the adrenal glands may cause Affected individuals may experience learning and developmental disability, difficulty swallowing, muscle weakness, weight loss, skin changes, vomiting, and coma.

SUBCHAPTER 3. TESTING OF NEWBORNS

310:550-3-1. Testing of newborns
(a) A blood sample from all newborns in Oklahoma shall be tested by a Certified Newborn Screening Laboratory for phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), X-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health; a parent or guardian may refuse screening of their newborn on the grounds that such examination conflicts with their religious tenets and/or practices the disorders approved by the Commissioner of Health and listed in 310:550-1-1.
(b) All newborns in Oklahoma shall be tested for CCHD by a pulse oximetry screening after twenty-four (24) hours of age or prior to discharge from the birthing facility.
(c) A parent or guardian who refuses the newborn screening blood test screening, hearing screening, and/or pulse oximetry screening of their newborn on the grounds that such examination conflicts with their religious tenets and/or practices; refusal of screening shall also be indicated in writing this refusal utilizing the Newborn Screening Program Parent Refusal Form provided by the program.
(d) The refusal form Newborn Screening Program Refusal Form shall include must be completed in its entirety the infant's name, date of birth, gender, demographic information, location of birth, name of the attending physician or provider, medical record number, indication of which screen is being refused (newborn blood test, newborn hearing screening, pulse oximetry screening), parent/guardian's printed name and signature as well as a witness' printed name, signature, and date. This signed refusal form shall be placed in the newborn's medical record with a copy sent to the Newborn Screening Program Coordinator.

SUBCHAPTER 5. BLOOD SPECIMEN COLLECTION

310:550-5-1. Specimen Blood specimen collection
(a) Specimen Blood specimen collection for hospital births. For all live hospital births, the physician, or licensed or certified birth attendant shall order the collection of a newborn screening blood specimen prior to transfusion, as early as possible after 24 hours of age or immediately prior to discharge, whichever comes first. Due to the need to promptly identify identification of infants newborns at risk for the screened disorders quickly is extremely important, the specimen shall be collected as early as possible after 24 hours of age. Specimens shall be collected on a single Newborn Screening Form Kit using capillary or venous blood. Cord blood is unacceptable. Umbilical cord blood is not recommended for use. The hospital is responsible for collecting specimens on all infants newborns.
   (1) If the initial specimen for any infant newborn is collected at or prior to 24 hours of age, the hospital and the physician are responsible for notifying the infant's newborn's parents parent(s) or guardian(s) verbally and in writing, utilizing the parent educational form on the Newborn Screening
Form Kit, that a repeat specimen is necessary at three to five days of age must be submitted as soon as possible after 24 hours of age. The infant's physician is responsible for ensuring that the repeat specimen is collected.

(2) The hospital is responsible for submitting a Satisfactory satisfactory Specimen specimen and for documenting all requested information on the Form Kit including the parent's/guardian's name, address, and phone or contact alternate phone number, the provider ordering the newborn screen, and the planned health care provider who will be providing well care for the infant after discharge. Or if the infant is to be hospitalized for an extended period of time, the name of the infant's physician.

(3) The hospital is responsible for documenting specimen collection and results in the infant's hospital record.

(4) Infants Newborns who are transferred from one hospital to another during the newborn period shall have specimen collection documented in the infant's hospital record. It is the responsibility of the infant's physician and the receiving hospital to ensure the specimen is collected and submitted to the Program.

(5) It is the responsibility of the hospital and physician to ensure that all infants newborns are screened prior to discharge. If an infant newborn is discharged prior to specimen collection, it is the responsibility of the hospital to notify the Newborn Screening Program Coordinator as soon as possible. The infant's physician is responsible for ensuring the specimen is collected as required.

(b) Screening for premature/sick infants newborns. For all premature/sick infants newborns, the physician shall order the collection of a newborn screening blood specimen prior to red blood cell transfusion, as early as possible after twenty-four (24) hours of age, but no later than three to seven days of age, or immediately prior to discharge, whichever comes first. Due to the need to identify infants newborns at risk for the screened disorders quickly, it is extremely important that the specimen should be collected as early as possible after twenty-four (24) hours of age. It is recommended that a repeat newborn screening specimen be collected at fourteen (14) days of age. Specimens shall be collected on the Newborn Screening Form Kit using capillary or venous blood. Umbilical cord blood is not recommended for use. The hospital and the physician are responsible for ensuring that specimens are collected on all premature/sick infants newborns.

(1) Premature/sick infants newborns screened at or prior to twenty-four (24) hours of age must be re-screened between seven to fourteen (7-14) days of age.

(2) Premature/sick infants newborns who could not be screened prior to a red blood cell transfusion should be screened by the seventh (7th) day of life, with a repeat specimen collected when plasma and/or red cells a blood specimen will again reflect the infant's newborn's own metabolic processes and hemoglobin type (the accepted time period to determine hemoglobin type is ninety to one hundred and twenty (90 to 120) days after transfusion).

(3) The recommended follow-up study for an abnormal thyroid screen in a premature infant newborn is a serum free T4 (measured by direct dialysis or an equivalent method) and TSH thyroid stimulating hormone (TSH) level at seven to fourteen (7-14) days of age.

(c) Specimen collection for out-of-hospital births.

(1) All infants newborns who are not born in a hospital shall be tested as early as possible after twenty-four (24) hours of age. The infant's physician, or licensed or certified birth attendant is responsible for submitting collection and submission of a Satisfactory satisfactory Newborn newborn Screening screening Specimen blood specimen as early as possible after twenty-four (24) hours of age. If there is not a physician, or licensed or certified birth attendant involved in a non-hospital birth, the person attending the birth and the parents of the infant newborn are responsible for submitting collection and submission of a Satisfactory satisfactory Newborn newborn Screening screening Specimen specimen.

(2) If a physician examines a child in the first three months of life who was not born in a hospital, or was born out of state, the physician will verify that the child has been screened. If the child has not
been screened or if results of screening are not available, the physician should be responsible for collecting and submitting a satisfactory newborn screening specimen.

310:550-5-2. Technique Guidelines for filter paper sample newborn screening blood specimen collection and pulse oximetry screening

(a) Filter paper sample newborn screening blood specimen collection.
   (1) Specimens obtained with a newborn screening form kit should be collected in accordance with the standard for Blood Collection on Filter Paper for Newborn Screening Programs, NBS01-A6, Sixth Edition, as adopted and published by the Clinical and Laboratory Standards Institute on July 31, 2013, or most recent version. Failure to follow these methods of blood collection may cause inaccurate results, or unsatisfactory specimen results, and require repeat specimen collection.
   (2) Submitters are responsible for submitting a satisfactory newborn screening specimen.

(b) Pulse oximetry screening.
   (1) Pulse oximetry screening. Pulse oximetry screening will be performed utilizing the hospital protocol. A recommended protocol is provided by the program.
   (2) Authorized provider. An authorized health care provider shall perform the pulse oximetry screening.
   (3) Newborn infants receiving routine care.
      (A) The duties of the birthing facility or nurse shall include the following:
         (i) Perform pulse oximetry screening on the newborn infant between twenty-four (24) hours and forty-eight (48) hours of life; or
         (ii) If unable to perform the pulse oximetry screening, schedule the infant to be screened at the facility between twenty-four (24) hours and forty-eight (48) hours of life, if unable to perform the pulse oximetry screening; or
         (iii) Notify the infant's physician if screening was not performed.
      (B) If the newborn infant is scheduled for discharge from a birthing facility after twelve (12) hours of life but before twenty-four (24) hours of life, the birthing facility shall perform pulse oximetry screening as late as is practical before the newborn infant is discharged from the birthing facility and shall notify the infant's physician of the early screening.
      (C) If the infant is discharged before twelve (12) hours of life, the birthing facility shall perform the pulse oximetry screening between twenty-four (24) hours and forty-eight (48) hours of life.
   (4) Newborn infants in special care or intensive care settings. Birthing facilities shall perform pulse oximetry screening on infants prior to discharge utilizing the hospital protocol recommended by the program, unless the infant has had an echocardiogram done performed. A recommended protocol is provided by the Program. Continuous pulse oximetry monitoring may not be substituted for CCHD screening.
   (5) Circumstances where pulse oximetry screening is not indicated. If pulse oximetry screening is not performed, the reason shall be documented on the newborn screening form kit. There may be instances where pulse oximetry screening for CCHD is not indicated, including but not limited to:
      (A) The clinical evaluation of the newborn infant's condition at birth has included an echocardiogram which ruled out CCHD; or
      (B) The newborn infant has been confirmed CCHD based on prenatal or postnatal testing.

SUBCHAPTER 7. HOSPITAL RECORDING RECORDS
310:550-7-1. Hospital recording records
(a) Newborn Screening screening blood test Results results.

(1) The hospital shall implement a procedure to ensure that a newborn screening blood specimen has been collected on every newborn and transported to the Newborn Screening Laboratory within twenty-four (24) to forty-eight (48) hours of collection. If more than one newborn screen is collected on an infant, each copy of the newborn screen kit should be placed in the infant's medical record. Specimens should be transported in the manner designated by the Department and or receiving laboratory.

(2) The hospital shall immediately notify the infant's physician, parent(s) or guardian(s), and Newborn Screening Program Coordinator if an infant is discharged without a sample having been collected. These notification shall be documented in the infant's hospital record.

(3) If no test results are not received by the hospital within fifteen (15) days after the date of collection, the hospital shall contact the Newborn Screening Laboratory to verify that a specimen had been received. If no specimen has been received, the hospital shall notify the physician.

(4) Any hospital or any other laboratory which collects, handles or forwards newborn screening samples shall keep a log containing the name and date of birth of the infant, name of the attending ordering physician, name of the planned health care provider who will be providing well care for the infant after discharge, medical record number, serial number of the Newborn Screening Form Kit used, date the specimen was drawn collection, date the specimen was forwarded sent to the certified laboratory, date the test results were transmitted or received and the test results.

(b) Pulse Oximetry oximetry Screening screening Results results.

(1) Recordation Record of Results results.

(A) All pulse oximetry screening results shall be recorded in the newborn infant's medical record and the results reported to a parent(s) or guardian(s) prior to discharge from the hospital.

(B) All pulse oximetry screening results shall be recorded on the Newborn Screening Form Kit, along with the following information:

(i) Newborn infant's:

(I) Name;

(II) Date of birth;

(III) Place of birth; and

(IV) Primary care physician after discharge; and

(ii) Mother's Name the infant's name, date of birth, submitting facility, mother's name, and the infant's physician.

(C) If the infant newborn is not screened for CCHD prior to the Newborn Screening Form Kit being forwarded to the Public Health Newborn Screening Laboratory for testing, fax documentation of CCHD screen results shall be communicated to the Oklahoma State Department of Health (OSDH) Newborn Screening (NBS) Program Coordinator utilizing the Pulse Oximetry Screening Result Form provided by the program.

(D) The pulse oximetry oximetry Screening screening Result form Form shall include must be completed in its entirety, the infant's name, date of birth, mother's name, primary physician, birth hospital, medical record number, date of pulse oximetry screening, age at time of screening, pulse oximetry screening result, reason pulse oximetry screening was not performed (if applicable), printed screener's name and signature, and date the form was signed.

(2) Abnormal Pulse pulse Oximetry oximetry Screen screen Results results.

(A) Abnormal It is the responsibility of the authorized health care provider who conducted the pulse oximetry screening to communicate abnormal results shall be reported by the authorized health care provider who conducted the screening to the attending physician or attending clinician
immediately.

(B) The newborn infant shall be evaluated immediately by an attending physician in order to complete the recommended protocol.

(C) The newborn infant may not be discharged from care until:
   (i) A cause for the abnormal pulse oximetry screen has been determined;
   (ii) An echocardiogram has been performed, read, and determined not to indicate CCHD; and/or
   (iii) A plan of care and follow-up has been established with the infant’s newborn’s parent(s) or guardian(s).

(D) The birthing facility shall report pulse oximetry screening results to the Department as specified in this regulation Chapter.

(E) It is the responsibility of the birthing facility shall to provide notification of the newborn’s parent(s) or guardian(s), the physician or clinician following the newborn in the hospital, and the infant’s physician of abnormal pulse oximetry results to the newborn infant’s:
   (i) Parent or guardian;
   (ii) Physician or clinician following the inpatient infant; and
   (iii) Primary care provider.

(3) Newborn Infants Not Screened for CCHD.

(A) If a newborn infant is not screened for CCHD secondary to discharge before 12 hours of life, the birthing facility shall:
   (i) Follow-up with the family parent(s) or guardian(s) to schedule screening of the infant newborn at their the birthing facility between twenty-four (24) and forty-eight (48) hours of life; or
   (ii) Follow-up with the family parent(s) or guardian(s) to schedule referral of the newborn to an authorized facility for screening between twenty-four (24) and forty-eight (48) hours of life after discharge from the facility; and
   (iii) Report screening results to the Department utilizing the Pulse Oximetry Screening Result Form provided by the program Program and indicating the reason for not screening which shall may be "early discharge".

(B) If the newborn infant pulse oximetry screening is not screened for CCHD secondary to screening not being indicated for the newborn, the birthing facility shall report results the reason for not screening, which may be "screening not indicated due to," and provide other CCHD findings for the newborn to the Department utilizing the form Pulse Oximetry Screening Result Form provided by the program Program and indicate the reason for not screening, which shall be "screening not indicated," with a notation for the reason pulse oximetry screening was not performed.

(C) If the newborn infant is not screened for CCHD secondary to because of parent or guardian refusal, the birthing facility shall fax send a refusal form the Newborn Screening Program Refusal Form to the Department utilizing the form provided by the program Program and indicate the reason for not screening, which shall may be "parent refusal".

SUBCHAPTER 11. ADVISORY COMMITTEE

310:550-11-1. Advisory committee

The Infant and Children’s Health Advisory Council shall advise the Department on newborn screening issues.

SUBCHAPTER 13. PARENT AND HEALTH CARE PROVIDER EDUCATION

310:550-13-1. Parent/Guardian and Health care Provider education

(a) The infant's physician or designee shall have the responsibility for ensuring
that at least one of each newborn’s parent or legal guardian of each newborn is notified about newborn screening and is provided information about the disorders and instructed how to obtain screen results from the planned health care provider or Newborn Screening Program.

(b) The infant's physician or designee shall have the responsibility to ensure is responsible for ensuring that at least one of each of the newborn's parent or legal guardian of each newborn is notified and provided information about the pulse oximetry screening and is provided information about the pulse oximetry screening and instructed how to obtain screen results from the birthing facility or the planned health care provider.

(c) The hospital birthing facility will be responsible or designate a responsible party is responsible for ensuring that at least one of each of the newborn's parent or legal guardian of each newborn is notified and provided information about the newborn screening and pulse oximetry screening and is provided information about the pulse oximetry screening and instructed how to obtain screen results from the planned health care provider.

(d) Hospitals Birthing facilities shall provide ongoing training programs for their employees involved with newborn screening and pulse oximetry screening procedures. These training programs shall include methods of collecting a satisfactory newborn screening blood specimen and proper pulse oximetry screening method.

(e) The hospital Birthing facilities is responsible for ensuring that employees who collect, and/or handle or perform newborn screening tests blood specimens or perform pulse oximetry screening are informed of their responsibilities with respect to screening procedures.

SUBCHAPTER 17. FOLLOW-UP FOR PHYSICIANS

310:550-17-1. Follow-up for physicians

(a) If a physician examines a child infant in the it's first three months of life, the physician will verify that the child infant has been screened, and document results in the infant's medical record. If the child infant has not been screened or if results of screening are not available, the physician should submit a Satisfactory newborn screening specimen within 48 hours of as soon as possible.

(b) On written notification by the Newborn Screening Program of follow-up requirements for a newborn screen result of abnormal, unsatisfactory, or for specimens collected from a newborn at or less than 24 hours of age at time of collection; the infant's physician or designee will obtain ensure that required repeat screening, confirmingatory testing, or diagnostic studies are performed, in the timeframe specified so that therapy, when indicated, can be initiated expeditiously.

(c) The infant's physician may selectively rescreen the infant as clinically indicated.

(d) Because patients may relocate without a forwarding address or contact information, where these rules place responsibility upon physicians and hospitals birthing facilities to notify parents have the burden to make a reasonable search and effort to locate and notify the parent(s) or guardian(s), that shall require only a reasonable search be made. If the parents parent(s) or guardian(s) are not contacted, then the Newborn Screening Program Coordinator shall be notified of the inability to notify after efforts to contact the parents the parent(s) or guardian(s) have been exhausted.

(e) For appropriate comprehensive medical care, all confirmed cases of congenital hypothyroidism, galactosemia, phenylketonuria, sickle cell disease, cystic fibrosis, congenital adrenal hyperplasia, medium chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short-term follow-up services, and approval by the Commissioner of Health a disorder on the newborn screening blood testing panel, should have a referral to a pediatric subspecialist subspecialist, and the parents parent(s) or guardian(s) should be referred for enrollment in newborn screening long-term follow-up services as designated by the Newborn Screening Program. For referral information, please contact the Newborn Screening Short-term Follow-up Program at (405) 271-6617 or
SUBCHAPTER 19. REPORTING

310:550-19-1. Physician Reporting and Medical Records

(a) If confirmatory or follow-up testing is not performed by the Newborn Screening Laboratory or through a contract laboratory designated by the Newborn Screening Program, the infant's physician must report the results of confirmatory follow-up testing to the Newborn Screening Program Coordinator within seven (7) days after the completion of the medical evaluation, using the Department's Newborn Screening Report Form provided by the program of the infant.

(b) The report form shall include the infant's name, date of birth, newborn screening laboratory number, mother's name, final diagnosis, notation of initiation of treatment and start date, notation of referral to pediatric subspecialist, notation if family was referred to other services, printed name and signature of physician determining diagnosis, telephone number and date form is completed. A copy of the confirmatory test results must accompany the report form.

(c) For all diagnosed cases of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA), x-linked adrenoleukodystrophy (X-ALD), mucopolysaccharidosis type I (MPS I) and Pompe disease upon completion of laboratory validation studies, establishment of short term follow up services, and approval by the Commissioner of Health, the infant's physician shall report treatment date if applicable, and referral information to the Newborn Screening Program Coordinator by completing the Department's Newborn Screening Report Form provided by the program.

(d) These newborn screening reports shall be confidential and may be utilized only for the purpose of ensuring service delivery, program administration, data analysis, and evaluation.

(e) On request, a birthing facility or health care provider shall make available to the NBS Newborn Screening Program or Oklahoma Birth Defects Registry:

1. Medical records;
2. Records of laboratory test; and
3. Any other medical information considered necessary to:
   A. Determine final outcomes of abnormal CCHD screening results; and
   B. Evaluate CCHD screening activities in the State; including:
      i. Performance of follow-up evaluations and diagnostic tests;
      ii. Initiation of treatment when necessary; and
      iii. Surveillance of the accuracy and efficacy of the screening.

(f) Information that the Department receives under this chapter is confidential and may only be used or disclosed:

1. To provide services to the newborn infant and the infant's family;
2. To study the relationships of the various factors determining the frequency and distribution of CCHD;
3. For State or federally mandated statistical reports; and
4. To ensure that the information received by the Department is accurate and reliable.

SUBCHAPTER 21. INFORMATION

310:550-21-1. Information

(a) For information regarding laboratory procedures, or results of laboratory tests, or to order kits, contact the Public Health Laboratory Service, Oklahoma State Department of Health, P.O. Box 1-800-766-2223 ext. 6617.
(b) For general information or information regarding follow-up for newborn screening or pulse oximetry screening, contact Newborn Screening Short-term Follow-up Program, Oklahoma State Department of Health, 1000 NE Tenth Street 123 Robert S. Kerr Avenue, Oklahoma City, Oklahoma 73117-1299 73102, (405) 271-6617 426-8220, option 2 or 1-800-766-2223, option 2, FAX (405) 271-4892, 1-800-766-2223, ext. 6617 900-7556. General information about the Newborn Screening Program is available on the OSDH Newborn Screening Web site website at www.health.ok.gov http://nsp.health.ok.gov.

SUBCHAPTER 23. STANDARDS, PROCEDURES, AND FOLLOW-UP FOR CERTIFIED LABORATORIES

310:550-23-1. Procedures
(a) The Commissioner of Health shall establish procedures for newborn screening laboratories which that shall include laboratory methodology, proficiency testing, quality assurance, sample collection, reporting, follow-up, handling, use, retention, storage and disposition of form kits.
(b) The Commissioner of Health shall establish procedures for the Department's newborn screening short-term follow-up program which that shall include quality assurance, notification of providers and parents parent(s) or guardian(s), follow-up guidelines, and parent parent or guardian and provider education.
(c) Hospitals Birthing facilities, physicians, and laboratories shall comply with procedures for the Newborn Screening Program established by the Commissioner of Health.
(d) Any laboratory performing newborn screening tests shall be certified by the Department as a Newborn Screening Laboratory. In order to be certified as a Newborn Screening Laboratory, a laboratory shall maintain technical proficiency and ensure that test reagents and equipment are properly standardized.
(e) A Certified Laboratory refers to the Oklahoma State Public Health Laboratory or a laboratory approved by the Oklahoma State Department of Health to conduct newborn screening tests. A laboratory desiring certification as a Newborn Screening Laboratory shall make written application to the Public Health Laboratory Service of the Department. A certified laboratory shall meet the following minimum standards:

(1) Eligibility for approval. A laboratory in Oklahoma that meets the requirements of Section 353 of the Public Health Service Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), Public Law 100-578. The Laboratory must have a CLIA certificate for tests of High Complexity and meet the criteria for those tests as specified in CLIA '88 and amendments. The lab laboratory must have the capacity to provide testing for the mandated newborn screening panel on a single satisfactory filter paper specimen Newborn Screening Form Kit submitted by the birth birthing hospital facility or provider.
(2) Minimum tests. A laboratory shall perform a sufficient number of tests each week test, a minimum of 300 blood samples specimens from different Oklahoma infants a week each week, to maintain technical proficiency and ensure that test reagents and equipment are properly standardized.
(3) Record keeping.
   (A) The laboratory shall log in each sample specimen received with an using at least two unique identifier identifiers. All patient information and test results shall be are linked to the identifier and maintained as a permanent record for a period of at least twenty-one (21) years.
   (B) The laboratory shall maintain quality control, and proficiency test records, and shall which shall be available for inspection by the Department.
   (C) If the laboratory should close, records must be maintained for the same time period. Records may be given to the Department for maintenance.
(4) Standard laboratory screening assay methods. All assay methods must be approved by the Commissioner of Health.
(5) **Follow-up for certified laboratories.**
(A) Within fifteen (15) days after specimen collection, the Certified Laboratory shall send a written report of the test results with repeat testing requirements, if indicated, to the submitter and physician listed on the filter paper requisition Newborn Screening Form Kit.
(B) The Certified Laboratory will reject any unsatisfactory specimens for testing.
(C) The Certified Laboratory must maintain a secure database with the capacity to report abnormal test results to the Department's Newborn Screening Program Coordinator or designee.
(D) The Certified Laboratory must report abnormal test results that are possible disease conditions within eight (8) to twenty-four (24) hours to the Department's Newborn Screening Program Coordinator or designee.

(6) **Activity Reporting reports.** Certified Laboratories shall compile quarterly and annual reports of total screening tests, abnormal tests by disorder, unsatisfactory tests, and for specimens collected from newborns at or less than twenty-four (24) hours of age at time of collection test for submission to the Newborn Screening Program.

(7) **Certification of laboratories.**
(A) A Certificate of Approval will be issued upon satisfying the requirements of these standards and demonstrating proficiency in the presence of an authorized representative from the Department. This Certificate of Approval will specify:
   (i) Name of laboratory
   (ii) Test of certification must be approved for all mandated tests.
   (iii) Date of issue and expiration: certificate issued for one (1) year and renewable annually.

(8) **Revocation of certification.**
(A) The laboratory shall be in compliance with all applicable Federal or and State Laws, or and regulations. The compliance with the requirements thereof shall be is the responsibility of the laboratory, without reliance on or direction by the Oklahoma State Department of Health. Following notice by the Department of its intent to revoke the laboratory's certification and completion of an individual proceeding pursuant to Article II of the Oklahoma Administrative Procedures Act (APA), the certification of a laboratory may be revoked, based upon proof by a preponderance of the evidence for any of the following reasons:
   (i) Failure to meet any requirements in these regulations; or
   (ii) Failure to use a standard laboratory assay approved by the Commissioner of Health; or
   (iii) Failure to participate in a recognized proficiency program and/or maintain proficiency; or
   (iv) Failure to keep adequate records of test results and quality control; or
   (v) Failure to give prompt notice of changes in personnel performing the tests or supervising testing.
(B) Upon notice of revocation the laboratory shall cease to perform newborn screening and return their certificate of approval.
(C) Reinstatement of laboratory certification shall be is contingent upon the following:
   (i) A laboratory shall not cannot apply for reinstatement until a minimum of three months has elapsed from date of revocation; and
   (ii) All factors which that lead to revocation of certification can be identified must be are corrected; and
   (iii) A laboratory applying for reinstatement must meet the same requirements as for initial application.
(D) Revocation of certified laboratory status by OSDH the Department may be appealed pursuant to Article II of the Oklahoma APA.